CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Total	Series A convertible preferred stock [Member]	Series A-1 convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Preferred Stock [Member] Series A convertible preferred stock [Member]	Preferred Stock [Member] Series A-1 convertible preferred stock [Member]	Preferred Stock [Member] Series B convertible preferred stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2022					$ 47,458	$ 4,132	$ 59,855
Beginning balance, Shares at Dec. 31, 2022					2,286,874	312,094	2,625,896
Beginning balance, Shares at Dec. 31, 2022								343,550
Beginning balance at Dec. 31, 2022	$ (130,712)							$ 1	$ 2,625		$ (133,338)
Exercise of stock options, Shares								3,575
Exercise of stock options	15								15		0
Stock-based compensation expense	296								296		0
Other comprehensive loss	0
Net Income (Loss)	(6,838)										(6,838)
Ending balance, Shares at Mar. 31, 2023					2,286,874	312,094	2,625,896
Ending balance at Mar. 31, 2023					$ 47,458	$ 4,132	$ 59,855
Ending balance, Shares at Mar. 31, 2023								347,125
Ending balance at Mar. 31, 2023	(137,239)							$ 1	2,936		(140,176)
Beginning balance at Dec. 31, 2023					$ 47,458	$ 4,132	$ 59,855
Beginning balance, Shares at Dec. 31, 2023		2,286,873	312,094	2,625,896	2,286,873	312,094	2,625,896
Beginning balance, Shares at Dec. 31, 2023								359,569
Beginning balance at Dec. 31, 2023	(182,921)							$ 1	4,159		(187,081)
Conversion of convertible preferred stock to common stock in connection with the Merge, Share					(2,286,873)	(312,094)	(2,625,896)	5,224,863
Conversion of convertible preferred stock to common stock in connection with the Merger, Value	111,445				$ (47,458)	$ (4,132)	$ (59,855)	$ 1	111,444
Issuance of common stock in the pre-closing financing, net of issuance costs of $X, Shares								1,682,045
Issuance of common stock in the pre-closing financing, net of issuance costs of $X, Value	42,000								42,000
Issuance of common stock for conversion of convertible notes, Shares								1,433,410
Issuance of common stock for conversion of Convertible Notes, Value	22,705								22,705
Issuance of common stock to homology shareholders in reverse recapitalization, Shares								3,229,633
Issuance of common stock to homology shareholders in reverse recapitalization	64,292								64,292
Reverse recapitalization transaction costs	(10,013)								(10,013)
Issuance of CVR at fair value	$ (180)								(180)
Exercise of stock options, Shares	0
Stock-based compensation expense	$ 417								417
Other comprehensive loss	(5)									$ (5)
Net Income (Loss)	1,029										1,029
Ending balance, Shares at Mar. 31, 2024		0	0	0	0	0	0
Ending balance at Mar. 31, 2024					$ 0	$ 0	$ 0
Ending balance, Shares at Mar. 31, 2024								11,929,520
Ending balance at Mar. 31, 2024	$ 48,769							$ 2	$ 234,824	$ (5)	$ (186,052)